Compare CNDT & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | NNNN |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United States | Germany |
| Employees | 51000 | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.2M | 163.7M |
| IPO Year | 2016 | 2023 |
| Metric | CNDT | NNNN |
|---|---|---|
| Price | $1.50 | $3.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 915.3K | 51.5K |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,042,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $3.09 |
| 52 Week High | $2.63 | $44.73 |
| Indicator | CNDT | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 32.29 |
| Support Level | $1.31 | $3.09 |
| Resistance Level | $1.62 | $6.95 |
| Average True Range (ATR) | 0.08 | 0.53 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 37.50 | 25.50 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).